

Discovery of novel TTK (MPS1) inhibitors for the TNBC treatment

Korea Research Institute of Chemical Technology (KRICT)



ONCOLOGY	Lead
Product Type	Chemical Product
Indication	1st Indication: Triple Negative Breast Cancer
Target	TTK (MPS1)
MoA(Mechanism of Action)	SAC break-through anti-cancer mechanism Induce massive aneuploidy and multinucleated cells
Competitiveness	1. Effective in the in vivo efficacy models with very low systemic drug exposure 2. Effective against taxane-resistant models
Development Stage	Lead
Route of Administration	Enteral – Oral